Study of TAK-781 in healthy people and PSC patients
Part of Digestive system clinical trials.
This study tests an investigational drug called TAK-781 in healthy volunteers and in people with primary sclerosing cholangitis (PSC) who do not have cirrhosis. The study aims to see how the drug is processed by the body and whether it is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- If you do not have PSC: you must be a healthy volunteer aged 18 to 68 with a BMI under 30.
- If you have PSC: your disease must not have led to cirrhosis, and you must have moderate to advanced liver scarring (fibrosis) as measured by a special blood test.
- You cannot have had your gallbladder removed, have a history of bile duct cancer, or have certain other liver diseases.
- You must not use heavy amounts of cannabis, alcohol, or tobacco, and cannot take certain other medications.
- Women who can become pregnant must use effective birth control; men must also use effective contraception.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a treatment made from mouth bacteria can help people with primary sclerosing cholangitis (PSC). It aims to see if it's safe and improves health.
This Phase 2 trial studies a “detoxification” approach to improve liver and bile-duct function in people with primary sclerosing cholangitis (PSC). It may help lower abnormal bile flow markers and see whether the treatment is safe for your liver.
This study tests a medication called norucholic acid for people with primary sclerosing cholangitis who already took part in an earlier trial of the same drug. It’s meant for those who either finished the previous study or stopped early because the drug wasn’t helping.
This study looks at what drives primary sclerosing cholangitis (PSC) and how it affects the body, using a team approach and medical tests like scans and blood work. It may help researchers understand PSC better and could improve future treatment decisions.
This study collects bile and uses it to grow small lab models (organoids) from people with primary sclerosing cholangitis (PSC) and from people without PSC. Researchers want to better understand how PSC changes bile cells, which could improve future diagnosis or treatments.
This study creates a national database for people diagnosed with primary sclerosing cholangitis (PSC). It may help researchers learn more about the condition by collecting health information from participants.
Hear when a new Primary Sclerosing Cholangitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.